Shinta Cheng

2.7k total citations · 1 hit paper
39 papers, 1.6k citations indexed

About

Shinta Cheng is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Shinta Cheng has authored 39 papers receiving a total of 1.6k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 14 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Shinta Cheng's work include Prostate Cancer Treatment and Research (26 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (8 papers). Shinta Cheng is often cited by papers focused on Prostate Cancer Treatment and Research (26 papers), Radiopharmaceutical Chemistry and Applications (11 papers) and Cancer, Lipids, and Metabolism (8 papers). Shinta Cheng collaborates with scholars based in United States, United Kingdom and Canada. Shinta Cheng's co-authors include Simon Chowdhury, Kim N., Hirotsugu Uemura, Vahid Naini, Byung Ha Chung, Andrea Juliana Gomes, Margaret K. Yu, Anders Bjartell, Ke Zhang and Mustafa Özgüroğlu and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Shinta Cheng

38 papers receiving 1.6k citations

Hit Papers

Apalutamide for Metastatic, Castration-Sensitive Prostate... 2019 2026 2021 2023 2019 250 500 750
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
    2019 891 citations Kim N., Neeraj Agarwal et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shinta Cheng United States 13 1.3k 537 441 432 257 39 1.6k
Angela Lopez‐Gitlitz United States 14 1.8k 1.3× 676 1.3× 368 0.8× 587 1.4× 235 0.9× 62 1.9k
Diletta Bianchini United Kingdom 22 1.6k 1.2× 755 1.4× 659 1.5× 768 1.8× 356 1.4× 68 2.1k
Julie S. Larsen United States 13 1.3k 1.0× 494 0.9× 322 0.7× 416 1.0× 303 1.2× 31 1.8k
Andrea Juliana Gomes United States 8 1.4k 1.0× 496 0.9× 336 0.8× 450 1.0× 152 0.6× 24 1.5k
Martin Boegemann Germany 19 1.2k 0.9× 630 1.2× 430 1.0× 388 0.9× 228 0.9× 90 1.4k
Carmel Pezaro United Kingdom 21 1.8k 1.4× 631 1.2× 498 1.1× 792 1.8× 466 1.8× 60 2.2k
Vahid Naini United States 8 1.1k 0.8× 417 0.8× 244 0.6× 357 0.8× 138 0.5× 21 1.2k
Mary B. Todd United States 18 2.1k 1.6× 739 1.4× 605 1.4× 691 1.6× 428 1.7× 54 2.5k
Daniel Petrylak United States 6 1.9k 1.4× 726 1.4× 813 1.8× 592 1.4× 453 1.8× 8 2.4k
Kris Deprince United States 7 948 0.7× 333 0.6× 252 0.6× 312 0.7× 168 0.7× 15 1.2k

Countries citing papers authored by Shinta Cheng

Since Specialization
Citations

This map shows the geographic impact of Shinta Cheng's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shinta Cheng with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shinta Cheng more than expected).

Fields of papers citing papers by Shinta Cheng

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shinta Cheng. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shinta Cheng. The network helps show where Shinta Cheng may publish in the future.

Co-authorship network of co-authors of Shinta Cheng

This figure shows the co-authorship network connecting the top 25 collaborators of Shinta Cheng. A scholar is included among the top collaborators of Shinta Cheng based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shinta Cheng. Shinta Cheng is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Shearer, Todd, Mark C. Johnson, Ewa Cendrowicz, et al.. (2024). Kinetics of Nirogacestat-Mediated Increases in B-cell Maturation Antigen on Plasma Cells Inform Therapeutic Combinations in Multiple Myeloma. Cancer Research Communications. 4(12). 3114–3123.
2.
Konstantinopoulos, Panagiotis A., et al.. (2023). Trial in progress: A phase two trial of nirogacestat, a gamma-secretase inhibitor, in patients with recurrent ovarian granulosa cell tumors (NCT05348356) (1284). Gynecologic Oncology. 176. S177–S178. 2 indexed citations
3.
Shearer, Todd, Mark P. Johnson, Ewa Cendrowicz, et al.. (2023). Population pharmacokinetic-pharmacodynamic model of nirogacestat effects on B-cell maturation antigen in healthy subjects.. Journal of Clinical Oncology. 41(16_suppl). 8027–8027. 2 indexed citations
4.
5.
Lonial, Sagar, Sebastian Grosicki, Marek Hus, et al.. (2022). Synergistic effects of low-dose belantamab mafodotin in combination with a gamma-secretase inhibitor (nirogacestat) in patients with relapsed/refractory multiple myeloma (RRMM): DREAMM-5 study.. Journal of Clinical Oncology. 40(16_suppl). 8019–8019. 17 indexed citations
6.
7.
Fendler, Wolfgang P., Manuel Weber, Amir Iravani, et al.. (2019). Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clinical Cancer Research. 25(24). 7448–7454. 183 indexed citations
8.
9.
Smith, Matthew R., Fred Saad, Simon Chowdhury, et al.. (2019). Predictors of falls and fractures in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with apalutamide (APA) plus ongoing androgen deprivation therapy (ADT).. Journal of Clinical Oncology. 37(15_suppl). 5025–5025. 13 indexed citations
10.
11.
12.
13.
Thomas, Shibu, Felix Y. Feng, Michael Gormley, et al.. (2019). PD11-03 RESPONSE TO APALUTAMIDE (APA) AMONG PATIENTS (PTS) WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER (NMCRPC) FROM SPARTAN BY DECIPHER GENOMIC CLASSIFIER (GC) SCORE. The Journal of Urology. 201(Supplement 4). 3 indexed citations
14.
Mainwaring, Paul N., Eric J. Small, Hiroji Uemura, et al.. (2018). Efficacy and safety of apalutamide (APA) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC) from SPARTAN: Asian subpopulation. Annals of Oncology. 29. ix68–ix68. 4 indexed citations
15.
Araujo, John C., Géralyn C. Trudel, Fred Saad, et al.. (2013). Overall survival (OS) and safety of dasatinib/docetaxel versus docetaxel in patients with metastatic castration-resistant prostate cancer (mCRPC): Results from the randomized phase III READY trial.. Journal of Clinical Oncology. 31(6_suppl). LBA8–LBA8. 36 indexed citations
16.
Wilding, George, Edwin M. Posadas, Mitchell E. Gross, et al.. (2008). Dasatinib in patients with hormone-refractory progressive prostate cancer: A phase II study. Journal of Clinical Oncology. 26(15_suppl). 5156–5156. 26 indexed citations
17.
Talpaz, Moshe, Jane F. Apperley, D. W. Kim, et al.. (2006). Dasatinib (D) in patients with accelerated phase chronic myeloid leukemia (AP-CML) who are resistant or intolerant to imatinib: Results of the CA180005 ’START-A’ study. Journal of Clinical Oncology. 24(18_suppl). 6526–6526. 15 indexed citations
18.
Evans, T. R. J., Annick D. Van den Abbeele, Iain McPherson, et al.. (2005). Phase I dose-escalation study of the SRC and multi-kinase inhibitor BMS-354825 in patients (pts) with GIST and other solid tumors. Journal of Clinical Oncology. 23(16_suppl). 3034–3034. 26 indexed citations
19.
Dy, Grace K., Laura M. Bruzek, Gary A. Croghan, et al.. (2004). A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3066–3066. 1 indexed citations
20.
Dy, Grace K., Laura M. Bruzek, Gary A. Croghan, et al.. (2004). A phase I trial of the farnesyltransferase (FT) inhibitor, BMS-214662 (B) in combination with paclitaxel (P) and carboplatin (C) in patients with advanced cancer. Journal of Clinical Oncology. 22(14_suppl). 3066–3066. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Angela Lopez‐Gitlitz Breakdown of academic impact, for papers by Diletta Bianchini Breakdown of academic impact, for papers by Julie S. Larsen Breakdown of academic impact, for papers by Andrea Juliana Gomes Breakdown of academic impact, for papers by Martin Boegemann Breakdown of academic impact, for papers by Carmel Pezaro Breakdown of academic impact, for papers by Vahid Naini Breakdown of academic impact, for papers by Mary B. Todd Breakdown of academic impact, for papers by Daniel Petrylak Breakdown of academic impact, for papers by Kris Deprince
Rankless by CCL
2026